Puma Biotechnology, Inc. (PBYI) fair value analysis
Nasdaq · Updated 2026-10-19
PBYI price how computed
Forward Fair Value verdict
OvervaluedPBYI is trading at more than a 25% premium to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $9.83
- Sector
- Healthcare
- 12-month range
- $4.73–$10.52
- Market cap
- $507M
- From 52-week high
- -6.6%
- Shares outstanding
- 51.6M
- Rank in Healthcare by discount to fair value
- #95 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Puma Biotechnology, Inc. is a biopharmaceutical company that develops and commercializes oncology drugs focused on treating various forms of cancer. The company operates in the United States and internationally, conducting research, development, and sales of its pharmaceutical products.
PBYI currently ranks #95 of 108 Healthcare stocks by discount to fair value. It has screened as Overvalued for 4 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $507M
- P/E (trailing)
- 17x
- Revenue (TTM)
- $231M
- Net margin
- 11.6%
- EPS (TTM)
- $0.59
- Gross margin
- 77.9%
- Debt / equity
- 0.03
- Revenue growth (3-yr avg)
- 0.2%
- Shares outstanding
- 51.6M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Expanding
- 52-week position
- The top quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 51 · neutral
- 50-day average
- $9.45
- 200-day average
- $7.68
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Earnings how computed
- Next earnings report
- 2026-11-05
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+166.7%)
2026-03 ▲ beat (+69.2%)
2025-12 ▲ beat (+36.8%)
2025-09 ▲ beat (+133.3%)
2025-06 ▲ beat (+50.0%)
2025-03 ▲ beat (+400.0%)
2024-12 ▲ beat (+207.1%)
2024-09 ▲ beat (+18.4%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Consensus price target
- $6
- Target vs last price
- -39.0%
What our data shows for PBYI
- Our model validated 12 trailing price-to-earnings windows for PBYI, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $4.73–$10.52.
- The 14-day relative strength index sits at a neutral 51.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for PBYI
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent PBYI news
TickrTrends' derived news-sentiment signal for PBYI is currently leaning negative, computed from recent coverage.
- PBYI Looks 165.9% Overvalued on GF Value™ (gurufocus.com, 2026-09-17)
TickrTrends take: PBYI is trading at a significant premium to its GF Value assessment, which aligns with TickrTrends' determination that the stock is overvalued within the Healthcare sector. For investors focused on valuation metrics, this divergence suggests the current market price substantially exceeds fundamental value estimates, indicating a potential risk of price correction if market sentiment shifts. Monitoring whether PBYI can justify its elevated valuation through earnings growth or other operational improvements will be critical for valuation-conscious investors tracking this Healthcare company. - Puma Biotechnology: NERLYNX Funds Their Potential Next Oncology Franchise (NASDAQ:PBYI) (seekingalpha.com, 2026-09-08)
TickrTrends take: Puma Biotechnology's reliance on NERLYNX revenue to support development of additional oncology programs occurs within a context where TickrTrends currently assesses the stock as overvalued. Investors monitoring the company's valuation should track whether new oncology pipeline progress can justify the current market price or whether execution risks may validate the overvalued assessment. The Healthcare sector backdrop suggests scrutiny of both NERLYNX's sustained commercial performance and the timeline and costs associated with bringing next-generation oncology candidates to market.
What people are saying
Follow the PBYI conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for PBYI have shifted this week, with the DCF cross-check band moving from no previous assessment to an overvalued classification. The valuation verdict has progressed from awaiting full valuation to overvalued, indicating that recent analysis now suggests the stock's current price exceeds its estimated intrinsic value based on the applied valuation models.
- 2026-10-05 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is PBYI stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), PBYI is trading at more than a 25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.
What is PBYI's TickrTrends verdict?
PBYI's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.
How does PBYI compare to other Healthcare stocks?
PBYI ranks #95 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is PBYI overbought or oversold?
PBYI's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does PBYI report earnings next?
PBYI's next earnings report is scheduled for 2026-11-05, per the published earnings calendar.
Does PBYI usually beat earnings estimates?
Over its last 8 reported quarters PBYI beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
More in Healthcare
Head-to-head comparisons
PBYI vs ALKS · PBYI vs CDNA · PBYI vs CRL · PBYI vs HUM · PBYI vs ILMN